MX2022013301A - Métodos y composiciones para tratar las afecciones inflamatorias asociadas con una enfermedad infecciosa. - Google Patents

Métodos y composiciones para tratar las afecciones inflamatorias asociadas con una enfermedad infecciosa.

Info

Publication number
MX2022013301A
MX2022013301A MX2022013301A MX2022013301A MX2022013301A MX 2022013301 A MX2022013301 A MX 2022013301A MX 2022013301 A MX2022013301 A MX 2022013301A MX 2022013301 A MX2022013301 A MX 2022013301A MX 2022013301 A MX2022013301 A MX 2022013301A
Authority
MX
Mexico
Prior art keywords
compositions
conditions associated
methods
infectious disease
inflammatory conditions
Prior art date
Application number
MX2022013301A
Other languages
English (en)
Inventor
Timothy Alexander Moseley
Kenneth Allen Pettine
Kevin Hicok
Original Assignee
Direct Biologics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Direct Biologics Llc filed Critical Direct Biologics Llc
Publication of MX2022013301A publication Critical patent/MX2022013301A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/366—Thrombomodulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Endocrinology (AREA)
  • Dispersion Chemistry (AREA)

Abstract

Se divulgan en la presente composiciones que comprenden una preparación de células madre mesenquimales (MSC) y una o más biomoléculas y el uso de dichas composiciones para el tratamiento de una infección microbiana o los síntomas o las afecciones patológicas secundarias asociados con dicha infección.
MX2022013301A 2020-04-22 2021-04-22 Métodos y composiciones para tratar las afecciones inflamatorias asociadas con una enfermedad infecciosa. MX2022013301A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063013865P 2020-04-22 2020-04-22
US202063198706P 2020-11-06 2020-11-06
PCT/US2021/028686 WO2021216903A1 (en) 2020-04-22 2021-04-22 Methods and compositions for treating inflammatory conditions associated with infectious disease

Publications (1)

Publication Number Publication Date
MX2022013301A true MX2022013301A (es) 2023-02-14

Family

ID=78270105

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022013301A MX2022013301A (es) 2020-04-22 2021-04-22 Métodos y composiciones para tratar las afecciones inflamatorias asociadas con una enfermedad infecciosa.

Country Status (11)

Country Link
US (2) US12590310B2 (es)
EP (1) EP4138867A4 (es)
JP (1) JP2023523588A (es)
KR (1) KR20230004709A (es)
CN (1) CN115843253A (es)
AU (2) AU2021261384B2 (es)
BR (1) BR112022021445A2 (es)
CA (1) CA3180973A1 (es)
IL (1) IL297563A (es)
MX (1) MX2022013301A (es)
WO (1) WO2021216903A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021526556A (ja) 2018-05-30 2021-10-07 ダイレクト バイオロジクス エルエルシー 成長因子および細胞外小胞を凍結または粉状にした、間葉系幹細胞（ｍｓｃ）の調製物を含む助剤、ならびにその使用方法
BR112021015549A2 (pt) 2019-02-07 2021-10-26 Direct Biologics Llc Método para tratar osteoartrite com uma combinação de exossomos de células tronco mesenquimais, células tronco mesenquimais sinoviais e andaimes
CA3146433A1 (en) 2019-07-18 2021-01-21 Direct Biologics Llc Preparations comprising mesenchymal stem cells and cannabinoids and methods of their use
US12590310B2 (en) 2020-04-22 2026-03-31 Direct Biologics, Llc Methods and compositions for treating inflammatory conditions associated with infectious disease
KR102317052B1 (ko) * 2020-05-04 2021-10-25 주식회사 티에스셀바이오 태반 유래의 세포외 소포의 항염증 항바이러스 효과 조성물
CN113789333B (zh) * 2021-09-07 2023-07-14 中国人民解放军军事科学院军事医学研究院 Chi3l1在调控hUC-MSCs抑制Th17分化介导的免疫调节作用上的应用
CN118414437A (zh) 2021-12-21 2024-07-30 学校法人关西医科大学 结核感染试样的筛选方法和用于该方法的探针组
CN114469996B (zh) * 2021-12-23 2023-10-20 中国医学科学院医学生物学研究所 一种包含miR-135b-5p的外泌体及在抗轮状病毒感染中的应用
JP2025511272A (ja) * 2022-03-29 2025-04-15 ダイレクト バイオロジクス エルエルシー Ｒｎａを含むセクレトームおよびその使用方法
CN115478117A (zh) * 2022-05-11 2022-12-16 江苏命码生物科技有限公司 一种用于早期预警新型冠状病毒中重型、危重型病例的试剂盒
US11878036B2 (en) 2022-05-25 2024-01-23 Neuvian LLC Vaginal care compositions and methods of improving vaginal health
JP7406059B1 (ja) 2022-10-20 2023-12-27 防衛装備庁長官 急性ストレス評価用データの生成方法
CN116656699B (zh) * 2023-05-16 2024-05-31 南京农业大学 SESN2和chi-miR-130b-3p在调节由玉米赤霉烯酮诱导的颗粒细胞凋亡中的应用
CN116515995B (zh) * 2023-06-29 2023-09-19 迈杰转化医学研究(苏州)有限公司 一种检测噬血细胞性淋巴组织细胞增生症的血清microRNA标志物及其应用
CN116875550B (zh) * 2023-09-08 2023-12-26 天津市肿瘤医院（天津医科大学肿瘤医院） 一种FABP4+C1q+巨噬细胞及其制备方法和用途
US12502407B2 (en) 2024-04-25 2025-12-23 Direct Biologics, Llc Treatment of fistula with bone marrow mesenchymal stem cell derived extracellular vesicles
WO2025226276A1 (en) * 2024-04-25 2025-10-30 Direct Biologics, Llc Treatment of fistula with bone marrow mesenchymal stem cell derived extracellular vesicles
CN118459570B (zh) * 2024-07-10 2024-11-12 南京领源生物科技有限公司 一种能改善胰岛素分泌和增殖功能的多肽pdmhs2
CN118909053B (zh) * 2024-10-11 2025-01-28 南京农业大学三亚研究院 抗菌肽或其盐、药物组合物及应用

Family Cites Families (214)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1601438A (es) 1968-10-17 1970-08-24
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
CA2018228C (en) 1989-06-05 1996-02-27 Nancy L. Parenteau Cell culture systems and media
US5135917A (en) 1990-07-12 1992-08-04 Nova Pharmaceutical Corporation Interleukin receptor expression inhibiting antisense oligonucleotides
AU749675B2 (en) 1998-03-13 2002-07-04 Mesoblast International Sarl Uses for human non-autologous mesenchymal stem cells
GB9807639D0 (en) 1998-04-14 1998-06-10 Kennedy Rheumatology Inst Anti-inflammatory agents
FR2785543B1 (fr) 1998-11-05 2003-02-28 Inst Nat Sante Rech Med Exosomes modifies et utilisations
US6372494B1 (en) 1999-05-14 2002-04-16 Advanced Tissue Sciences, Inc. Methods of making conditioned cell culture medium compositions
US7311905B2 (en) 2002-02-13 2007-12-25 Anthrogenesis Corporation Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells
AU2002353907A1 (en) 2001-10-26 2003-06-30 Steven A. Baranowitz Methods for treating wounds using melanin and related substances
DE10224982A1 (de) 2002-06-05 2003-12-24 Rolf Hoffmann Mesenchymale Stammzellen des Haarfollikels und deren Verwendung
US20040248970A1 (en) 2003-04-10 2004-12-09 Webster G.R. Barrie CBD-delta8-THC composition
EP2399990B1 (en) 2003-06-27 2015-07-22 DePuy Synthes Products, Inc. Cells derived from post-partum umbilical cord for use in treatment of disease of the heart and circulatory system
WO2006036213A2 (en) 2004-04-29 2006-04-06 Pediamed Pharmaceuticals, Inc. The use of gammaglobulin for the treatment of periodontal disease
KR100668371B1 (ko) 2004-12-30 2007-01-12 한훈 제대혈 유래 줄기세포를 이용한 대머리 치료
JP2008544957A (ja) 2005-05-10 2008-12-11 ユナイテッド ステイツ オブ アメリカ デパートメント オブ ヴェテランズ アフェアーズ 間充織幹細胞による腎疾患及び多臓器不全の治療法と間充織幹細胞馴化培地
EP1940445B1 (en) 2005-08-19 2011-02-02 Duke University Stem cell derived paracrine factor h12 for use in reducing cell death or enhancing tissue repair
US20070254827A1 (en) 2006-04-27 2007-11-01 The Regents Of The University Of California Alpha-aminobenzyl-alpha,alpha,-diphosphoric acid selective chelation of beryllium
US20090304644A1 (en) 2006-05-30 2009-12-10 Cytori Therapeutics, Inc. Systems and methods for manipulation of regenerative cells separated and concentrated from adipose tissue
WO2007149548A2 (en) 2006-06-22 2007-12-27 Medistem Laboratories, Inc. Treatment of erectile dysfunction by stem cell therapy
JP5656183B2 (ja) 2006-08-22 2015-01-21 国立大学法人 東京医科歯科大学 滑膜由来間葉幹細胞（ＭＳＣｓ）の軟骨・半月板再生への応用
WO2008024996A2 (en) 2006-08-24 2008-02-28 Johnstone Brian H Production of neural protective and regenerative factors from stem cells and treatment of nervous system conditions therewith
CA2711218C (en) 2008-01-04 2019-08-06 Lydac Neuroscience Limited A method of producing a population of differentiated cells
US20090177487A1 (en) 2008-01-07 2009-07-09 Tera Eerkes Methods for Assessing Genetic Compatibility
CN102014934B (zh) 2008-02-22 2014-08-20 新加坡科技研究局 间充质干细胞颗粒
BRPI0909866B1 (pt) 2008-06-11 2021-08-24 Fresenius Medical Care Deutschland Gmbh Método de produção de um meio condicionado de células progenitoras de fígado, meio condicionado e composição farmacêutica
CN102439136A (zh) 2009-03-26 2012-05-02 加州大学校董 产生用于疾病修饰的抑制性rna的间充质干细胞
CA2763927A1 (en) 2009-06-05 2010-12-09 Skinrephair Ltd. Use of stem cells from hair root sheaths and keratinocyte precursor cells for the regeneration of aged skin
WO2011024172A2 (en) 2009-08-27 2011-03-03 Technion Research & Development Foundation Ltd. Liposomal compositions and uses of same
WO2011099007A1 (en) 2010-02-10 2011-08-18 Nayacure Therapeutics Ltd. Pharmaceutical compositions and methods for the treatment and prevention of cancer
WO2011118795A1 (ja) 2010-03-26 2011-09-29 国立大学法人名古屋大学 損傷部治療用組成物
CA2802880C (en) 2010-06-18 2019-09-24 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Hair follicle neogenesis
EP3470057B1 (en) 2010-09-29 2021-11-03 Pulmatrix Operating Company, Inc. Cationic dry powders comprising magnesium salt
ES2746554T3 (es) 2010-11-02 2020-03-06 Univ Columbia Métodos para tratar los trastornos de pérdida de cabello
WO2012087241A1 (en) 2010-12-20 2012-06-28 Agency For Science, Technology And Research Method of purifying exosomes
CA2829586C (en) * 2011-03-11 2021-03-02 Children's Medical Center Corporation Methods and compositions relating to mesenchymal stem cell exosomes
WO2012142569A2 (en) 2011-04-15 2012-10-18 The Regents Of The University Of California Decellularized extracellular matrix
EP2721179A4 (en) 2011-06-16 2014-10-01 Caris Life Sciences Luxembourg Holdings S A R L BIOMARKER COMPOSITIONS AND METHOD THEREFOR
US8494123B2 (en) 2011-07-01 2013-07-23 Apple Inc. On-hold visual menu from a user's communications device
ITRM20110403A1 (it) 2011-07-28 2013-01-29 Ospedale Pediatrico Bambino Gesu Microvescicole isolate da cellule mesenchimali come agenti immunosoppressori.
EP2771454B1 (en) 2011-10-27 2019-07-24 Universität Leipzig Method for deriving melanocytes from the hair follicle outer root sheath and preparation for grafting
US20130129688A1 (en) 2011-11-09 2013-05-23 Allocure, Inc. Assay for the Prediction of Therapeutic Effectiveness or Potency of Mesenchymal Stem Cells, and Methods of Using Same
ES2661236T3 (es) 2011-12-13 2018-03-28 Henry Ford Health System Procedimientos, sistemas y composiciones para administración de microARN derivado de células/a base de vesículas
US9427450B2 (en) 2012-01-31 2016-08-30 Xon Cells, Inc. Therapeutic immune modulation by stem cell secreted exosomes
CA2866563A1 (en) 2012-03-07 2013-09-12 Fibrocell Technologies, Inc. Topical dermal formulations and methods of personalized treatment of skin
SG11201406336YA (en) 2012-04-03 2014-11-27 Reneuron Ltd Stem cell microparticles
JP2015518485A (ja) 2012-04-20 2015-07-02 アプタミアール セラピューティクス インコーポレイテッド 熱発生のｍｉＲＮＡ調節剤
EP2850178A4 (en) 2012-05-18 2015-10-28 Agency Science Tech & Res EXOSOMES OF MESHCHYMIC STROKE CELL OF UMBILICAL CORD
AU2013286812B2 (en) 2012-07-04 2017-04-20 Zz Biotech Llc Treatment of inflammatory skin disorders
EP2687219A1 (en) 2012-07-18 2014-01-22 Universität Duisburg-Essen Use of preparations comprising exosomes derived from mesenchymal stem cells (MSCs) in the prevention and therapy of inflammatory conditions
CA2879322A1 (en) 2012-07-19 2014-01-23 Reneuron Limited Stem cell microparticles
CU24121B1 (es) 2012-08-02 2015-08-27 Ct De Ingeniería Genética Y Biotecnología Vesículas que comprenden factor de crecimiento epidérmico y composiciones que las contienen
AU2013302799B2 (en) 2012-08-13 2018-03-01 Cedars-Sinai Medical Center Exosomes and micro-ribonucleic acids for tissue regeneration
EP4331620A3 (en) 2012-12-07 2024-12-04 Translate Bio, Inc. Lipidic nanoparticles for mrna delivery
US9408874B2 (en) 2013-02-15 2016-08-09 Kenneth Allen Pettine Regenerative autologous bone marrow cell therapies and methods for their use in the treatment of joint pain
US10058572B2 (en) 2013-08-15 2018-08-28 The Regents Of The University Of California Placenta-derived multipotent stem cells
US20160175485A1 (en) 2013-08-27 2016-06-23 The Regents Of The University Of California Combination therapy to promote wound healing
EP3052943B1 (en) 2013-10-04 2019-11-20 Cell Ideas Pty Ltd. Biomarkers for cell therapy
GB2520300A (en) 2013-11-15 2015-05-20 Univ Loughborough Cell Culture System
CA2947512A1 (en) 2014-05-01 2015-11-05 Stichting Vumc Small ncrnas as biomarkers
EP3204117A4 (en) 2014-10-06 2018-05-09 Cedars-Sinai Medical Center Polarization of macrophages to a healing phenotype by cardiosphere-derived cells and by the exosomes secreted by such cells
WO2016082882A1 (en) 2014-11-27 2016-06-02 Med Cell Europe Ag Secretomes and method for producing secretomes
RU2644650C2 (ru) 2014-12-01 2018-02-13 Общество с ограниченной ответственностью "Т-Хелпер Клеточные Технологии" Материал стволовых клеток и способ его получения
CN104622904A (zh) 2015-02-05 2015-05-20 山西医科大学 一种皮肤干细胞活性成分及其应用
EP3270984A4 (en) 2015-03-16 2019-04-17 Duncan Ross TREATMENT METHOD WITH MEMBRANE-INCLUDED VESICLE
GB201505747D0 (en) 2015-04-02 2015-05-20 Univ Bristol Exosomes
EP3286318A2 (en) 2015-04-22 2018-02-28 Mina Therapeutics Limited Sarna compositions and methods of use
AU2016261358B2 (en) 2015-05-11 2021-09-16 Editas Medicine, Inc. Optimized CRISPR/Cas9 systems and methods for gene editing in stem cells
WO2017001649A1 (en) 2015-07-02 2017-01-05 Med Cell Europe Ag Secretomes and method for producing secretomes
CN111150743A (zh) 2018-11-06 2020-05-15 中国医药大学 间质干细胞在治疗多发性硬化症的用途
EP3328413B1 (en) 2015-07-29 2024-09-04 Indiana University Research and Technology Corporation Materials and methods for treating and evaluating ischemic and/or reperfusion-injured tissue and/or tissue susceptible to same
WO2017023690A1 (en) 2015-07-31 2017-02-09 Exoceuticals, Inc. Exosome compositions and methods for preparation and use thereof for regulating and conditioning skin and hair
WO2017066663A1 (en) 2015-10-15 2017-04-20 Carromeu Cassiano Method of manufacturing cells using a hollow fiber bioreactor
KR102311832B1 (ko) 2015-10-16 2021-10-13 (주)프로스테믹스 줄기세포 유래 엑소좀을 포함하는 상처 치료, 피부 개선 및 탈모 방지 또는 치료용 조성물 및 그 제조방법
US20170121685A1 (en) 2015-11-02 2017-05-04 Tigenix S.A.U. Mesenchymal stem cell-derived exosomes and their uses
KR101765767B1 (ko) 2015-11-02 2017-08-07 희성촉매 주식회사 담체 계면 공극 집중 매몰형 scr 촉매 구조체
JP2019501179A (ja) 2015-12-30 2019-01-17 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 細胞由来ベシクルの向上された生成および単離のための方法
KR20170085010A (ko) 2016-01-12 2017-07-21 주식회사 강스템바이오텍 고함량의 성장인자를 함유한 줄기세포 유래 엑소좀
EP3922253A1 (en) 2016-01-15 2021-12-15 Orbsen Therapeutics Limited Sdc-2 exosome compositions and methods of isolation and use
CN109072189A (zh) 2016-02-12 2018-12-21 细胞治疗药物公司 脂肪组织衍生的间充质基质细胞条件培养基及其制备和使用方法
CN109069870B (zh) 2016-02-24 2022-04-29 洛克菲勒大学 基于胚胎细胞的用于亨廷顿氏病的治疗候选物筛选系统、模型及它们的应用
US20190000886A1 (en) 2016-03-16 2019-01-03 Duncan ROSS Method of treatment of osteochondral defects
JP2017180553A (ja) 2016-03-29 2017-10-05 トヨタ自動車株式会社 動力伝達装置
WO2017196798A1 (en) 2016-05-09 2017-11-16 Chang Jae-Hyung Robert Accelerated method for preparing platelet rich plasma
RU2708329C2 (ru) 2016-05-31 2019-12-05 Общество с ограниченной ответственностью "Т-Хелпер Клеточные Технологии" Материал стволовых клеток, композиции и способы применения
JP2019518760A (ja) 2016-06-15 2019-07-04 オーハイ エナジェティクス ピービーシー 幹細胞療法を増強するための方法および組成物
EP3842049A1 (en) 2016-07-18 2021-06-30 Brainstorm Cell Therapeutics Ltd. Methods for diagnosing amyotrophic lateral sclerosis (als)
CN109790516A (zh) 2016-07-29 2019-05-21 罗廷灿 制备抑制癌细胞增殖的间充质干细胞的方法
KR101977019B1 (ko) 2016-08-26 2019-05-10 연세대학교 산학협력단 중간엽 줄기세포 유래 분비 단백체를 포함하는 류마티스 관절염 치료용 약제학적 조성물 및 이를 이용한 치료 방법
KR20190039822A (ko) 2016-08-29 2019-04-15 해컨색 유니버시티 메디컬 센터 인간에서 혈소판-유사 세포를 함유하는 혈액의 혈소판 풍부 분획의 줄기세포능을 통해 성체 세포를 재프로그래밍하기 위한 조성물 및 방법
JP7177041B2 (ja) 2016-08-29 2022-11-22 ハッケンサック ユニヴァーシティ メディカル センター 血小板様細胞を含有する血液の血小板に富む画分を用いて成体細胞をプログラミングするための組成物および方法
EP3515474B1 (en) 2016-09-19 2026-03-04 Cambridge Innovation Technologies Consulting Limited Human asparaginase lacking glutaminase activity
US12161111B2 (en) 2016-09-23 2024-12-10 Peter Friedman Compositions and methods for treating citrus plants infected with bacteria and for promoting general agricultural health
US9980984B2 (en) 2016-10-13 2018-05-29 Kenneth Allen Pettine Treatment of inflammation of osteoarthritic knees with mesenchymal stem cells
IT201600109148A1 (it) 2016-10-28 2018-04-28 Pharmaexceed Srl Processo per isolare e liofilizzare vescicole extracellulari
MX2019005127A (es) 2016-11-03 2019-09-26 Exostem Biotec Ltd Poblaciones y productos de células madre mesenquimales y sus usos.
US10736359B2 (en) 2016-12-02 2020-08-11 VMR Products, LLC Cartridge-based vaporizers
US20180318356A1 (en) 2016-12-29 2018-11-08 Kenneth Allen Pettine Dermatological and cosmetic treatments using mesenchymal stem cells
EP3568143B1 (en) 2017-01-11 2023-12-13 Paracelsus Medizinische Privatuniversität Salzburg - Privatstiftung Mesenchymal stem cell-derived extracellular vesicles and their medical use
EP3569239A4 (en) 2017-01-11 2020-12-09 Stemlab Inc. METHOD OF PREPARING A COMPOSITION IN AN EXOSOME FROM NANG-INTRODUCED FETAL MESENCHYMAL STEM CELL IN THE FRUIT WATER FOR HAIR GROWTH
EP3568141B1 (en) 2017-01-16 2020-12-16 Cells for Cells S.A. Composition comprising a substantially pure population of multipotent stromal cells encapsulated in platelet-poor plasma (ppp)
US10987381B2 (en) 2017-01-27 2021-04-27 Neil Riordan Mesenchymal stem cells with enhanced efficacy in treatment of autoimmunity particularly rheumatoid arthritis
EP3576724B1 (en) 2017-02-01 2023-09-27 GBS Global Biopharma, Inc. Cannabinoid-containing complex mixtures for the treatment of mast cell-associated or basophil-mediated inflammatory disorders
WO2018150440A1 (en) 2017-02-16 2018-08-23 OCT Therapies and Research Private Limited Stem cell conditioned media for clinical and cosmetic applications
WO2018162696A1 (en) 2017-03-10 2018-09-13 Institut Pasteur Common genetic variations at the tcra-tcrd locus control thymic function in humans
US20180264043A1 (en) 2017-03-14 2018-09-20 Holding Pen, Llc Restoration of deteriorated tissue in the face or selected areas of the body with mesenchymal stem cells
US20180338866A1 (en) 2017-03-21 2018-11-29 Mohammad Ali Kharazmi Electroactive dressings
WO2018204764A1 (en) 2017-05-05 2018-11-08 Camp4 Therapeutics Corporation Identification and targeted modulation of gene signaling networks
US11529376B2 (en) 2017-05-05 2022-12-20 Capricor, Inc. Methods of treating systemic graft-versus-host disease with extracellular vesicles
US20200392219A1 (en) 2017-05-08 2020-12-17 Trustees Of Tufts College Extracellular vesicles comprising membrane-tethered tgf-beta, compositions and methods of use thereof
US20200188440A1 (en) 2017-05-16 2020-06-18 Exostem Biotec Ltd. Methods of inhibiting aging and treating aging-related disorders
US20200113943A1 (en) 2017-06-05 2020-04-16 The Regents Of The University Of California Methods for enhanced production and isolation of cell-derived vesicles and treatment of inflammation and neurological damage
CA3072562A1 (en) * 2017-08-15 2019-02-21 Children's Medical Center Corporation Purified mesenchymal stem cell exosomes and uses thereof
CA3073879A1 (en) 2017-08-24 2019-02-28 The Texas A&M University System Mesenchymal stem/stromal cell-derived extracellular vesicles and uses thereof in autoimmune diseases
CA3082880A1 (en) * 2017-11-16 2019-05-23 Celularity Inc. Cultivation of placenta to isolate exosomes
WO2019118817A1 (en) 2017-12-14 2019-06-20 Mayo Foundation For Medical Education And Research Purified exosome products, method of making, and methods of using
US11660355B2 (en) 2017-12-20 2023-05-30 Cedars-Sinai Medical Center Engineered extracellular vesicles for enhanced tissue delivery
CN108042572A (zh) 2017-12-27 2018-05-18 北京多赢时代转化医学研究院 治疗白癜风的产品及其使用方法和应用
US10717981B2 (en) 2018-01-18 2020-07-21 Advanced ReGen Medical Technologies, LLC Therapeutic compositions and methods of making and using the same
CN112384200A (zh) 2018-01-30 2021-02-19 希斯托金公司 低氧条件下培养的细胞衍生的胞外囊泡及其用途
CN108456655A (zh) 2018-02-23 2018-08-28 深圳至博生物科技有限公司 间充质干细胞悬浮液及其制备方法与应用
US20210000882A1 (en) 2018-02-28 2021-01-07 Crown Scientific, LLC Production and use of extracellular vesicles
US12233092B2 (en) 2018-04-10 2025-02-25 Brainstorm Cell Therapeutics Ltd. MSC-NTF specific exosomes and use thereof
CN108498452A (zh) 2018-04-10 2018-09-07 上海交通大学医学院附属仁济医院 一种用于治疗勃起功能障碍的含干细胞可注射水凝胶及其制备方法
CN112334190B (zh) * 2018-04-30 2024-09-20 儿童医学中心公司 间充质基质细胞外排体及其用途
EP3813896B1 (en) 2018-05-14 2025-10-01 Roosterbio, Inc. Methods and compositions related to extracellular material derived from hypertonic cell solutions
JP2021526556A (ja) 2018-05-30 2021-10-07 ダイレクト バイオロジクス エルエルシー 成長因子および細胞外小胞を凍結または粉状にした、間葉系幹細胞（ｍｓｃ）の調製物を含む助剤、ならびにその使用方法
US11866483B2 (en) 2018-06-08 2024-01-09 Kanoncure, Inc. Fibrosis-inhibiting composition, cells producing same, and cell sheet comprising said cells
WO2019246014A1 (en) 2018-06-18 2019-12-26 North Carolina State University Stem cell biomimetic nanoparticle therapeutic agents and uses thereof
US20210228643A1 (en) 2018-07-26 2021-07-29 Uniwersytet Jagiellonski N vivo delivery system of the genome dna modifying enzymes and the use thereof
US20200030253A1 (en) 2018-07-26 2020-01-30 Mohammad Ali Kharazmi Methods and compositions for treatment of body conditions
KR102163806B1 (ko) 2018-07-30 2020-10-07 주식회사 엑소코바이오 줄기세포 유래의 엑소좀을 유효성분으로 포함하는 피지분비 감소용 조성물
WO2020028526A1 (en) 2018-08-02 2020-02-06 Histogen, Inc. Conditioned medium and extracellular matrix compositions and uses thereof
AU2019319623B2 (en) 2018-08-08 2026-01-29 Theramir Ltd MicroRNA-based therapy targeted against LCP-1 positive cancers
US12371653B2 (en) 2018-08-24 2025-07-29 University Of Delaware Extracellular vesicles as biomarkers and therapeutics for neuromuscular disorders
WO2020061408A1 (en) 2018-09-21 2020-03-26 Tarachon Llc Cartilage regeneration by synovial fluid-derived stem cells and their derivatives
WO2020069313A2 (en) 2018-09-28 2020-04-02 Henry Ford Health System Use of extracellular vesicles in combination with tissue plasminogen activator and/or thrombectomy to treat stroke
US12263189B2 (en) 2018-10-18 2025-04-01 Nantbio, Inc. Mesenchymal stem cell derived exosomes and methods
KR20210121039A (ko) 2018-12-26 2021-10-07 다이렉트 바이오로직스 엘엘씨 피부 및 모발 장애를 치료하기 위한 방법 및 조성물
WO2020142769A1 (en) 2019-01-04 2020-07-09 Kenneth Allen Pettine Isolation and use of autogenous platelet derived exosomes
CN109718392B (zh) 2019-01-18 2021-11-26 广州润虹医药科技股份有限公司 复合型医用敷料及其制备方法
AU2020214832A1 (en) 2019-01-30 2021-08-19 Direct Biologics Llc Methods and compositions for developing target specific exosome and growth factor products
BR112021015549A2 (pt) 2019-02-07 2021-10-26 Direct Biologics Llc Método para tratar osteoartrite com uma combinação de exossomos de células tronco mesenquimais, células tronco mesenquimais sinoviais e andaimes
US20220195390A1 (en) 2019-02-07 2022-06-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for preparing extracellular vesicles (ev) depletemedia
JP2022519718A (ja) 2019-02-08 2022-03-24 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 加齢および加齢性臓器不全に関連する疾患の処置のためのテロメラーゼ含有エキソソーム
EP3927317A4 (en) 2019-02-19 2022-08-10 Direct Biologics, LLC ACELLULAR INTRAVENOUS INFUSION WITH GROWTH FACTORS FROM MESENCHYMAL STEM CELLS AND EXOSOMES
IT201900003639A1 (it) * 2019-03-13 2020-09-13 Evobiotech S R L Composizioni di vescicole extracellulari (EV) derivate da piante e loro usi
US20220175843A1 (en) 2019-04-08 2022-06-09 Symbiocell Tech, Llc Treatment of Microvascular Disorders with Mesenchymal Stem Cells and Their Exosomes
US10881693B2 (en) 2019-04-09 2021-01-05 Combangio, Inc. Processes for making and using a mesenchymal stem cell derived secretome
KR20220002317A (ko) 2019-04-29 2022-01-06 다이렉트 바이오로직스 엘엘씨 특징규명된 중간엽 줄기세포 성장인자 및 엑소좀을 이용한 치주 질환의 치료 방법
KR102049505B1 (ko) 2019-05-14 2019-11-29 이장호 젖산탈수소효소 b 및 페록시좀 증식인자-활성화 수용체 감마 활성화인자 1-알파가 함유된 면역관용화된 세포외소포의 제조방법 및 이를 이용한 항암용 조성물
CN118147051A (zh) 2019-06-10 2024-06-07 布瑞克斯奥根株式会社 用于促进干细胞来源外泌体产生和增加干性的包含白藜芦醇的组合物
PH12021553167A1 (en) 2019-06-19 2022-08-15 Celularity Inc Exosomes for disease treatment
IL289004B2 (en) 2019-06-26 2025-10-01 Technion Res & Dev Foundation Production of extracellular vesicles from stem cells
US20230144427A1 (en) 2019-07-12 2023-05-11 Vasanthi PALANIVEL Composition and methods for improving thickness and receptivity of endometrial lining
CA3146433A1 (en) 2019-07-18 2021-01-21 Direct Biologics Llc Preparations comprising mesenchymal stem cells and cannabinoids and methods of their use
EP4003305A4 (en) 2019-07-22 2023-07-26 Erivan Bio, LLC TOPICAL EXOSOME COMPOSITIONS AND RELATED METHODS
CN114269358A (zh) 2019-07-31 2022-04-01 上海圣特佳健康科技发展有限公司 针对纤维化、炎症、和/或老化疾病的治疗药物
US11138804B2 (en) 2019-08-02 2021-10-05 Fmr Llc Intelligent smoothing of 3D alternative reality applications for secondary 2D viewing
CN114938630A (zh) 2019-11-15 2022-08-23 尼奥普罗根公司 用于心脏修复的永生化心脏干细胞
CA3163871A1 (en) 2019-12-04 2021-06-10 United Therapeutics Corporation Extracellular vesicles and their uses
JP7674354B2 (ja) 2019-12-05 2025-05-09 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 肝線維症および線維症に関連する他の疾患に対するエキソソームベースの療法
JP7778377B2 (ja) 2020-01-20 2025-12-02 イーブイ、セル、バイオテック、（コアンチョウ）、カンパニー、リミテッド 小胞及びその使用
EP4114923A1 (en) 2020-03-05 2023-01-11 MVEX Japan, Inc. Extracellular vesicle compositions and the use thereof in the treatment of skin conditions and in immune modulation
WO2021181399A1 (en) 2020-03-12 2021-09-16 Exostem Biotec Ltd. Mesenchymal stromal cells and extracellular vesicles for treating viral infections, inflammation, and tissue fibrosis
US20230143893A1 (en) 2020-03-23 2023-05-11 Avem Holdings Llc Isolation and purification of exosomes for regenerative medicine
WO2021207282A2 (en) 2020-04-07 2021-10-14 Combangio, Inc. Lyophilized mesenchymal stem cell derived secretome and uses thereof
US12590310B2 (en) 2020-04-22 2026-03-31 Direct Biologics, Llc Methods and compositions for treating inflammatory conditions associated with infectious disease
KR102319735B1 (ko) 2020-04-28 2021-11-01 건국대학교 산학협력단 3차원 배양된 줄기세포로부터 세포외 소포체를 제조하는 방법
TW202146034A (zh) 2020-05-05 2021-12-16 美國商加速生物科學有限公司 包含有分泌蛋白體的藥學與化妝品組成物
EP4171596A1 (en) 2020-06-24 2023-05-03 Chameleon Biosciences, Inc. Extracellular vesicles with immune modulators
EP4179072B1 (en) 2020-07-09 2025-09-03 Exo Biologics Sa Process for the manufacturing of protein-associated extracellular vesicles
JP2023537204A (ja) 2020-07-09 2023-08-31 エクソ バイオロジクス エスアー 間葉系ストローマ細胞由来の細胞外小胞（ｅｖ）および前記ｅｖを得るための方法
US20230248773A1 (en) 2020-07-09 2023-08-10 Exo Biologics Sa Extracellular Vesicles and Compositions Thereof
WO2022018729A1 (en) 2020-07-20 2022-01-27 Brainstorm Cell Therapeutics Ltd. Methods and compositions for treating lung conditions
JP7848989B2 (ja) 2020-09-03 2026-04-21 学校法人自治医科大学 間葉系幹細胞又はそれに由来する前駆細胞の培養上清の浄化濃縮物、及びその製造方法
WO2022076419A1 (en) 2020-10-05 2022-04-14 Albert Einstein College Of Medicine Methods of treating viral infections with pirnas or extracellular vessicles released from neural stem cells or neural progenitor cells
US20220110970A1 (en) 2020-10-14 2022-04-14 The Texas A&M University System Engineered Extracellular Vesicle Delivery Systems and Uses Thereof
EP4240323A1 (en) 2020-11-06 2023-09-13 AATEC Medical GmbH A composition comprising extra-cellular vesicles from mesenchymal stem cells and alpha-1 antitrypsin for the treatment of viral infections
US11672761B2 (en) 2020-11-16 2023-06-13 Orcosa Inc. Rapidly infusing platform and compositions for therapeutic treatment in humans
WO2022150696A1 (en) 2021-01-11 2022-07-14 United Therapeutics Corporation Ev for use in treating myocarditis
JP2024506908A (ja) 2021-02-12 2024-02-15 モデルナティエックス インコーポレイテッド インビボ療法のためのペイロードを含むｌｎｐ組成物
US20240197832A1 (en) 2021-05-24 2024-06-20 University Of Pittsburgh – Of The Commonwealth System Of Higher Education Methods and materials for treating a stroke
WO2022265864A2 (en) 2021-06-04 2022-12-22 The Brigham And Women’S Hospital, Inc Tim-3 modulates anti-tumor immunity by regulating inflammasome activation
WO2022261636A1 (en) 2021-06-09 2022-12-15 Essent Biologics Tissue extracts and related methods
EP4355304A4 (en) 2021-06-17 2025-04-30 Malcolm, Thomas PERSONALIZED HYPOIMMUNE NANOVESICULAR DELIVERY SYSTEMS FOR CANCERS, INHERITED DISEASES AND INFECTIOUS DISEASES
FR3124696B1 (fr) 2021-06-30 2025-03-14 Tbf Genie Tissulaire Materiau biologique imprégné de vesicules lipidiques
US12187784B2 (en) 2021-07-02 2025-01-07 Combangio, Inc. Processes for making a cellular fibronectin composition
WO2023282424A1 (ko) 2021-07-06 2023-01-12 건국대학교 산학협력단 줄기세포 유래 세포외 소포체 및 이의 용도
WO2023281524A1 (en) 2021-07-06 2023-01-12 Suma Kantipudi Placenta derived mesenchymal stromal cell secretome, process and uses thereof
EP4374173A4 (en) 2021-07-21 2026-02-25 Mercy Bioanalytics Inc CANCER COMPOSITIONS AND DETECTION METHODS
WO2023021525A1 (en) 2021-08-16 2023-02-23 Lifecell International Pvt. Ltd A human amnion-chorion based wound dressing material and method thereof
WO2023024637A1 (zh) 2021-08-26 2023-03-02 中山大学 一种力学性囊泡的制备方法
KR102704051B1 (ko) 2021-08-30 2024-09-09 가톨릭대학교 산학협력단 세포 밖 소포체 함유 안표면 염증 질환 예방 또는 치료용 조성물
US20240408033A1 (en) 2021-10-15 2024-12-12 The Board Of Trustees Of The Leland Stanford Junior University Cell-derived nanovesicles for in vivo transport and delivery of therapeutic materials
WO2023075557A1 (ko) 2021-10-29 2023-05-04 주식회사 씨케이엑소젠 연골 항상성 인자를 포함하는 엑소좀 및 이를 포함하는 골관절염 예방 또는 치료용 조성물
US20250011780A1 (en) 2021-11-12 2025-01-09 University Of Ottawa Heart Institute Compositions of human heart derived extracellular vesicles and uses thereof
US20250032550A1 (en) 2021-11-16 2025-01-30 West Virginia University Board of Governors on behalf of West Virginia University A novel way for brain-specific delivery of molecules for the treatment of brain diseases
JPWO2023127645A1 (es) 2021-12-28 2023-07-06
WO2023123216A1 (zh) 2021-12-30 2023-07-06 中山大学 囊泡在制备治疗肺部疾病的药物中的应用
US20230226267A1 (en) 2022-01-19 2023-07-20 Semiflex Dome System Sp. Z.o.o. Dome catheter system for transcutaneous vacuum assisted closure of perianal or enterocutaneous abcesses and fistula tracts and method thereof
JP2025511272A (ja) 2022-03-29 2025-04-15 ダイレクト バイオロジクス エルエルシー Ｒｎａを含むセクレトームおよびその使用方法
WO2024192119A1 (en) 2023-03-14 2024-09-19 Direct Biologics, Llc Wound healing compositions and methods thereof
EP4724043A2 (en) 2023-06-09 2026-04-15 Direct Biologics, LLC Treatment of complex regional pain syndrome with extracellular vesicle composition
WO2024254540A2 (en) 2023-06-09 2024-12-12 Direct Biologics, Llc Treatment of amyotrophic lateral sclerosis with extracellular vesicle composition
TW202535437A (zh) 2023-11-07 2025-09-16 美商迪瑞克特生物製劑有限責任公司 使用胞外囊泡組合物之長新冠（ｌｏｎｇ ｃｏｖｉｄ）之治療
WO2025101659A1 (en) 2023-11-07 2025-05-15 Direct Biologics, Llc Extracellular vesicle composition for use in the treatment of irradiated skin
WO2025101658A1 (en) 2023-11-07 2025-05-15 Direct Biologics, Llc Extracellular vesicle composition for use in the treatment of lumbar facet joint syndrome
WO2025101663A1 (en) 2023-11-07 2025-05-15 Direct Biologics, Llc Extracellular vesicle composition for use in the treatment of graft-versus-host disease
WO2025189128A1 (en) 2024-03-08 2025-09-12 Direct Biologics, Llc Treatment of infertility with extracellular vesicle composition
WO2025199333A1 (en) 2024-03-21 2025-09-25 Direct Biologics, Llc Treatment of ehlers-danlos syndrome with extracellular vesicle composition
WO2025226866A1 (en) 2024-04-24 2025-10-30 Direct Biologics, Llc Bone marrow mesenchymal stem cell derived extracellular vesicles to improve perioral area and face fat graft retention
WO2025226863A1 (en) 2024-04-24 2025-10-30 Direct Biologics, Llc Treatment of traumatic brain injury with extracellular vesicle composition
WO2025226276A1 (en) 2024-04-25 2025-10-30 Direct Biologics, Llc Treatment of fistula with bone marrow mesenchymal stem cell derived extracellular vesicles

Also Published As

Publication number Publication date
AU2021261384A1 (en) 2022-12-22
KR20230004709A (ko) 2023-01-06
AU2021261384B2 (en) 2025-08-14
CA3180973A1 (en) 2021-10-28
US20230159932A1 (en) 2023-05-25
EP4138867A1 (en) 2023-03-01
IL297563A (en) 2022-12-01
US20250277217A1 (en) 2025-09-04
AU2025220828A1 (en) 2025-09-11
EP4138867A4 (en) 2024-05-01
US12590310B2 (en) 2026-03-31
US12570980B2 (en) 2026-03-10
JP2023523588A (ja) 2023-06-06
BR112022021445A2 (pt) 2023-01-10
WO2021216903A1 (en) 2021-10-28
CN115843253A (zh) 2023-03-24

Similar Documents

Publication Publication Date Title
MX2022013301A (es) Métodos y composiciones para tratar las afecciones inflamatorias asociadas con una enfermedad infecciosa.
CO2022001210A2 (es) Conjugados de il-2 y métodos de uso para tratar enfermedades autoinmunes
MX2023000859A (es) Composiciones y metodos relacionados con agentes terapeuticos activables.
CL2020002915A1 (es) Composiciones para el tratamiento de condiciones de la piel
MX2021009259A (es) Conjugados de il-2 y metodos de uso del mismo.
MX2018009917A (es) Vacuna contra el virus del zika.
CO2022010330A2 (es) Dosificación de gamma-hidroxibutirato (ghb)
ECSP20046463A (es) Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas
MX2020003995A (es) Nuevas moleculas de acido nucleico artificiales.
CR20200545A (es) Inhibidores magl
MX2025004075A (es) Vacunas para circovirus porcino tipo 3 (pcv3), y produccion y sus usos
MX2022001776A (es) Terapias de combinacion de inmuno oncologia con conjugados de il-2.
SV2011003888A (es) Compuestos que expanden las celulas madre hematopoieticas
UY32812A (es) Anticuerpos humanos de alta afinidad para angiopoyetina -2 humana.
CO2022000481A2 (es) Inhibidores de enzimas
CO2023014622A2 (es) Conjugados de anticuerpo-fármaco anti-c-met
CL2021002807A1 (es) Anticuerpos y métodos para el tratamiento de la infección por influenza a
DOP2023000219A (es) Compuestos de tienopirrol
MX2024002913A (es) Anticuerpos anti-siglec-6 y metodos de uso de los mismos.
MX2020010932A (es) Enzimas quinureninasa humanas y sus usos.
CO2023004381A2 (es) Anticuerpos cd1a y su uso
AR119979A1 (es) Anticuerpos contra el factor de las células madre y métodos de uso de ellas
MX2022012618A (es) Aptameros para uso en el tratamiento de infecciones por coronavirus.
CU20100056A7 (es) Método para inhibir la replicación del vih en células de mamíferos
MX2018006577A (es) Metodo para inactivar xenoantigenos en tejidos biologicos.